Choroidal Thickening Induced by Pioglitazone in Diabetic Patients
Korean Journal of Ophthalmology · 2024
DOI: 10.3341/kjo.2024.0039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Korean Journal of Ophthalmology, 2024. Verfasst von Ju Seouk Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Kosin University College of Medicine, Busan, Korea. Hauptthemen laut MEDLINE: Pioglitazone, Choroid, Hypoglycemic Agents, Diabetes Mellitus, Type 2. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Purpose
This study aimed to determine the changes in choroidal thickness induced by pioglitazone in diabetic patients.
Methods
A total of 261 patients diagnosed with type 2 diabetes who had taken oral pioglitazone for more than 6 months were included in the study. After excluding patients who did not undergo regular eye examinations or who had ophthalmic surgery/interventions during the treatment period, a total of 40 eyes were included. The study examined the duration and dosage of pioglitazone, patient age, ocular axial length, refraction, glycated hemoglobin, systolic blood pressure, corrected visual acuity, macular thickness, choroidal thickness, and choroidal vascular index. Patients were categorized into a high-dose group if their pioglitazone dose was 30 mg or more per day, and a low-dose group if it was 15 mg or less. Choroidal thickness was measured below the subfovea and a 500 µm radius nasal and temporal to that location.
Results
Choroidal thickness significantly increased after 6 and 12 months of pioglitazone (6.70 and 13.65 µm, respectively) in all subjects. When stratified by pioglitazone dosage, choroidal thickness increased at 6 and 12 months in both high-dose group (4.48 and 0.84 µm, respectively) and low-dose groups (6.85 and 21.45 µm, respectively), with a greater change observed in the low-dose group (p < 0.05). Based on the location of choroidal thickness measurements, a significant increase in choroidal thickness was observed at 6 and 12 months of pioglitazone treatment in the subfoveal (7.00 and 13.15 µm, respectively) and nasal regions (6.43 and 19.24 µm, respectively), while a significant increase was only observed after 6 months of treatment in the temporal region (8.53 µm, p < 0.05). The largest increase in choroidal thickness was observed in the nasal side.
Conclusions
This study found that choroidal thickness increased in diabetic patients after taking pioglitazone. Regular eye examinations are recommended for diabetic patients who are on pioglitazone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Kosin University College of Medicine, Busan, Korea.
Zitieren
APA
Lee, J. S., Kim, C. Z., Lee, S. U., & Lee, S. J. (2024). Choroidal Thickening Induced by Pioglitazone in Diabetic Patients. Korean Journal of Ophthalmology. https://doi.org/10.3341/kjo.2024.0039
Vancouver
Lee JS, Kim CZ, Lee SU, Lee SJ. Choroidal Thickening Induced by Pioglitazone in Diabetic Patients. Korean Journal of Ophthalmology. 2024. doi:10.3341/kjo.2024.0039
BibTeX
@article{Lee2024,
author = {Lee, Ju Seouk and Kim, Chang Zoo and Lee, Seung Uk and Lee, Sang Joon},
title = {Choroidal Thickening Induced by Pioglitazone in Diabetic Patients},
journal = {Korean Journal of Ophthalmology},
year = {2024},
doi = {10.3341/kjo.2024.0039}
}
EUVIMED